Atrys Health (CHIX:ATRYE) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ATRYE Atrys Health SA CHIX:ATRYE
65 GF Score
Price €6.08
GF Value €7.71
! 5 Warning Signs
View Full Analysis

What is Atrys Health Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Atrys Health Quality Rank Related Terms

CHIX:ATRYE
65GF Score
Atrys Health SA CHIX:ATRYE
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Atrys Health (CHIX:ATRYE) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €6.08 is trading 21.1% below its estimated GF Value™ of €7.71.

Key valuation signals for CHIX:ATRYE:

  • Quality Rank:
  • GF Value™: €7.71 vs. price of €6.08 (21.1% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CHIX:ATRYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges ATRY:SpainA2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
65GF Score

Get the complete analysis for CHIX:ATRYE

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.08
Price
€7.71
GF Value